Global Companion Diagnostics (CDx) Market to 2025 - Market is Expected to Reach $4.1 Billion

DUBLIN, Oct. 2, 2018 /PRNewswire/ --

The "Global Companion Diagnostics (CDx) Market: Focus on Technology, Indication, Country-wise Analysis, Regulatory Framework, and Competitive Landscape - Analysis and Forecast, 2018-2025" report has been added to ResearchAndMarkets.com's offering.

The global companion diagnostics market is expected to reach $4.1 billion by 2025.

In the era of precision medicine, the number of commercialized predictive biomarker assays has increased tremendously, especially in case of chronic diseases, to facilitate the development of targeted therapeutics. These biomarker-based assays, known as companion diagnostics (CDx), not only aid in parallel development of targeted drugs, but also provide essential information for patient stratification to enable effective and safe use of corresponding treatment. Till date, healthcare industry has witnessed several successful drug-diagnostic co-developments mostly for oncology.

However, successful commercialization and approval of CDx for multiple cancer types, including lung cancer, breast cancer, leukemia, colorectal cancer, gastric cancer, ovarian cancer, and melanoma, have further drawn attention of several pharmaceutical and diagnostic companies to venture into this lucrative market by developing non-oncology CDx solutions, especially for indications such as neurodegenerative diseases, infectious diseases, metabolic disorders, and cardiovascular diseases, thereby enhancing the growth of global CDx market.

With increasing demand for NGS-based companion diagnostics, the global CDx market is expected to witness double digit growth rate during the forecast period 2018-2025. In addition, PCR-based companion diagnostics is expected to be dominating among the other technology-based products, in 2025. In 2017, companion diagnostics for lung cancer was responsible for a 27.20% share of the global market value.

The purpose of the study is to gain a holistic view of the global companion diagnostics market in terms of various factors such as recent trends and technological advancements, influencing the market. The scope of this report is centered upon conducting a detailed study of the products allied with the companion diagnostics market, which includes various technology-based products such as Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next Generation Sequencing (NGS), and Polymerase Chain Reaction (PCR). However, the market estimation only comprises manufacturers of companion diagnostics. The companion diagnostics market is segmented into three different parts namely technology, indication, and region. The global market value was estimated using these three different approaches and was validated with one another. These segments are further segmented into several sub-segments to ease the market estimation and to gain a holistic view of the market.

Based on the region, the global companion diagnostics market is segmented into North America, Europe, Asia-Pacific, and Rest-of-the-World (RoW). North America is the leading contributor to the global companion diagnostics market and was responsible for a 52.53% share of the global market values in 2017. However, Asia-Pacific is expected to grow at a CAGR of 32.06% during the forecast period 2018-2025.

Key Topics Covered:

Executive Summary

1 Market Overview
1.1 Classification of Companion Diagnostics (CDx)
1.2 CDx in a Historical Perspective
1.3 Constituents for Companion Diagnostics (CDx) Development
1.4 Significant Applications of Companion Diagnostics (CDx)
1.5 Companion Diagnostics (CDx): Future Potential

2 Market Dynamics
2.1 Overview
2.2 Iceberg Analysis
2.3 Impact Analysis
2.4 Market Drivers
2.4.1 Growing Incidence of Cancer
2.4.1.1 Better Treatment Assurance
2.4.1.2 Diagnostic and Treatment Availability for All Forms of Cancer
2.4.2 Growing Demand of Precision Medicine
2.4.2.1 Adverse Drug Reactions
2.4.2.2 Boost in Predictive Biomarker Discovery
2.4.3 Co-Development of Drugs and Diagnostics
2.5 Market Restraints
2.5.1 Uncertain Reimbursement Scenario
2.5.2 Companion Diagnostics Leakage in Oncology
2.5.3 Weak Synchronization between Therapeutics and Diagnostics in Marketing and Distribution Channels
2.6 Opportunities within the Market
2.6.1 New Indication Areas
2.6.2 Next Generation Sequencing Accelerating Targeted Gene Therapy
2.6.3 Data Science for Companion Diagnostics Applications

3 Competitive Insights
3.1 Key Strategies and Developments
3.2 Joint Ventures, Partnerships, and Collaborations
3.3 Product Approvals
3.4 Acquisitions
3.5 Product Launches and Other Developments
3.6 Market Share Analysis
3.7 Growth Share Analysis

4 Regulatory Framework
4.1 Legal Requirements and Framework by the FDA
4.2 Legal Requirements and Framework by the EMA
4.3 Legal Requirements and Framework by the MHLW

5 Global Companion Diagnostics Market: Analysis and Forecast
5.1 Assumptions & Limitations for Market Size Calculations
5.2 Market Overview

6 Global Companion Diagnostics Market (by Technology)
6.1 Overview
6.2 Polymerase Chain Reaction (PCR)
6.3 Immunohistochemistry (IHC)
6.4 In-situ Hybridization (ISH)
6.5 Next Generation Sequencing (NGS)

7 Global Companion Diagnostics Market (by Indication)
7.1 Overview
7.2 Lung Cancer
7.3 Breast Cancer
7.4 Colorectal Cancer
7.5 Stomach Cancer
7.6 Leukemia
7.7 Melanoma
7.8 Others
7.9 Non-Oncology Diseases

8 Global Companion Diagnostics Market (by Region)
8.1 Overview
8.2 North America
8.3 Europe
8.4 Asia-Pacific
8.5 Rest-of-the-World

9 Company Profiles

• Abbott Laboratories
• Agilent Technologies, Inc.
• ARUP Laboratories
• bioMrieux SA
• Danaher Corporation
• F. Hoffmann-La Roche AG
• Illumina, Inc.
• Invivoscribe Technologies, Inc.
• MolecularMD Corporation
• Myriad Genetics, Inc.
• QIAGEN N.V.
• Thermo Fisher Scientific Inc.
• ArcherDx, Inc.
• Exosome Diagnostics, Inc.
• NeoGenomics, Inc.
• MDxHealth, Inc.
• NanoString Technologies, Inc.

For more information about this report visit https://www.researchandmarkets.com/research/vhrx86/global_companion?w=5

Media Contact:

Laura Wood, Senior Manager
[email protected]  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-companion-diagnostics-cdx-market-to-2025---market-is-expected-to-reach-4-1-billion-300722750.html

SOURCE Research and Markets